Metsä Board achieves Leadership status in CDP 2016 Forest programme


Metsä Board, part of Metsä Group, has achieved Leadership status in the materials sector of CDP’s 2016 Forest Programme for the second year in a row. This follows swiftly on the news that CDP recently recognised Metsä Board’s management of water security and climate change with A-List positions in both programmes. CDP (formerly Carbon Disclosure Project)is the international not-for-profit organisation that drives sustainable economies.
The CEO Mika Joukio was invited to take part in a discussion panel at the CDP Global Water Forum on 15 November in Marrakesh where the water results were revealed. You can listen to his viewpoints from the video.

For Metsä Board, a key part of sustainable forestry is forest renewal. “Here in Finland, four new seedlings are planted for each harvested tree. Metsä Group delivers seedlings to forest-owners for planting, and during the past couple of years this has amounted annually to 30 million seedlings, which is an impressive number,” says Mika Joukio, Metsä Board’s CEO.

Visit Metsa’s booth

Gerresheimer Duma Pocket 100 ml: handy and child-safe


Does a tablet container always have to look like a pharmaceutical container? The Duma Pocket’s oval shape makes it look more like a box of sweeteners or peppermints. Gerresheimer is introducing a new member of the Duma Pocket product family: Duma Pocket 100 ml.

The new Duma Pocket can be used to dispense tablets. It is also available in 30 and 50 ml sizes. Another advantage is that it can be sent by post because it conforms to the post box standard (DS/EN 17324).

Lots of space for branding

The side surfaces of the oval shape are useful for displaying consumer information, and they are also large enough for distinctive branding. The lid area can be used for customer-specific labelling.

Moisture protected

A desiccant in the base reliably absorbs moisture. The maximum volume, not including the space occupied by the desiccant, is up to 100 ml. Like all other Duma Pocket products, Duma Pocket 100 ml is made of polypropylene (PP).

All colors

The container can be manufactured in any color, even in translucent or transparent. Its height is 80.5 mm and has the dimensions of 70 x 30 mm. The new Duma Pocket is manufactured with an injection moulding process under clean conditions.


High-speed filling and FDA-registered

Duma Pocket containers are suitable for high-speed filling processes,  they can be compactly packaged and are easily stored. Filling sizes of 75 and 125 mm can be also manufactured using the same base.

Duma Pocket is FDA registered, DMF type III, DMF no. 12077 and also satisfies European Regulations (EC) no. 1935/2004, (EC) no. 2023/2006 and EU no. 10/2011 on materials and articles intended to come into contact with food.

The new Duma Pocket design is so ergonomic that the user only needs one hand to hold and open the oval box. It has an integrated closure with dispensing aid, a tamper evident seal, and it is also senior-friendly and child-resistant.

Visit Gerresheimer’s booth

Catalent Acquires Accucaps To Expand Softgel Development And Manufacturing Capabilities And Capacity


Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced that it has agreed to acquire Accucaps Industries Limited (Accucaps), the Canada-based developer and manufacturer of Over-the-Counter (OTC), high potency and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed.

The acquisition, which is subject to Canadian governmental approval, will substantially complement Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity with the addition of a portfolio of products supplied to pharmaceutical companies in North America, and two state-of-the-art facilities offering integrated softgel development, manufacturing and packaging, strengthening Catalent’s ability to offer customers turnkey solutions.

Commenting on the acquisition, Dr. Aris Gennadios, Catalent’s President of Softgel Technologies, said, “Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments.”

Upon completion of the acquisition, Accucaps’ over 500 employees, at its two facilities in Windsor and Strathroy, Ontario, will join Catalent’s global network of 11 Softgel Technologies facilities. The Accucaps facilities house sizeable blistering, bottling and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s.

Visit Catalent’s booth

FAREVA opens a new aerosol manufacturing line in Henrico, US


Fareva opened on December 7th a $40 million expansion at its Richmond, VA plant. It has a capacity to manufacture about 100 million aerosol cans annually for drug, OTC and beauty products.

Located in a former distribution building adjacent to the main production plant, the expansion of the aerosol plant is adding 80 to 100 jobs to the 745,000-square-foot manufacturing plant and office facility in Richmond. The acquisition of the facility in 2011 from Pfizer saved about 500 jobs.

Now Fareva has 35 production sites worldwide, more than $1.5 billion in revenue, and a workforce of nearly 10,000 people; 600 in Henrico County.

The new facility has a flame-proof bulk manufacturing workshop, an R&D laboratory for the product development and three aerosol packaging lines, including one with “bag on valve” capability.

Fareva is already considering a second upgrade expansion at the plant, which would require as much as a $15 to $20 million investment to take the aerosol plant’s capacity to 250 million aerosol cans and add 150 more jobs.

Fareva also has plans to add a 5,000-square-foot research lab at the plant that would employ about 20 scientists, technicians and engineers.

Want to learn more? Don’t hesitate to contact us on our booth.

Visit Fareva’s booth

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery


Partnership combines IBM Watson’s cognitive computing capabilities with Pfizer’s scientific knowledge to help scientists generate meaningful insights

A collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer’s research in immuno-oncology, an approach to cancer treatment that uses the body’s immune system to help fight cancer. Pfizer is one of the first organizations worldwide to deploy Watson for Drug Discovery, and the first to customize the cloud-based cognitive tool – tapping in to Watson’s machine learning, natural language processing, and other cognitive reasoning technologies to support the identification of new drug targets, combination therapies for study, and patient selection strategies in immuno-oncology.

Immunotherapies, which modify a patient’s immune system to recognize and target cancer cells using a combination of vaccines, immunomodulators, and small/large molecules, are reshaping the field of oncology. Oncology researchers at Pfizer will use Watson for Drug Discovery to analyze massive volumes of disparate data sources, including licensed and publicly available data as well as Pfizer’s proprietary data. With this new tool, Pfizer researchers will analyze and test hypotheses to generate evidence-based insights for real-time interaction. The customized technology can also support efficient safety assessments.

Cancer is one of the leading causes of death worldwide, and is arguably one of the most complex diseases known to mankind.1 Many researchers believe that the future of immuno-oncology lies in combinations tailored to unique tumor characteristics, which could transform the cancer treatment paradigm and enable more oncology patients to be treated.

“Pfizer remains committed to staying at the forefront of immuno-oncology research,” said Mikael Dolsten, President, Pfizer Worldwide Research & Development. “With the incredible volume of data and literature available in this complex field, we believe that tapping into advanced technologies can help our scientific experts more rapidly identify novel combinations of immune-modulating agents. We are hopeful that by leveraging Watson’s cognitive capabilities in our drug discovery efforts, we will be able to bring promising new immuno-oncology therapeutics to patients more quickly.”

Laurie Olson, Executive Vice President, Strategy, Portfolio and Commercial Operations, Pfizer, said, “At Pfizer, we are entering a new frontier in data innovation in which we are investing in a range of new technologies and digital solutions to help us dynamically mine both internal and external data sources to find new connections in science, as well as help us better understand how diseases progress and how they could potentially be treated. Applying the power of cognitive computing to an area that is a core part of our DNA – discovering new medicines – is helping Pfizer to learn how we can most efficiently discover those immuno-oncology therapies that have the best chance of successful outcomes for patients.”

The newly launched Watson for Drug Discovery is a cloud-based offering that aims to help life sciences researchers discover new drug targets and alternative drug indications. The average researcher reads between 200 and 300 articles in a given year2, while Watson for Drug Discovery has ingested 25 million Medline abstracts, more than 1 million full-text medical journal articles, 4 million patents and is regularly updated.  Watson for Drug Discovery can be augmented with an organization’s private data such as lab reports and can help researchers look across disparate data sets to surface relationships and reveal hidden patterns through dynamic visualizations.

“We believe that the next great medical innovations will emerge as researchers and scientists find new patterns in existing bodies of knowledge. In order to do this, they need access to R&D tools that can help them efficiently navigate the opportunities and challenges presented by the explosion of data globally,” said Lauren O’Donnell, Vice President of Life Sciences, IBM Watson Health. “IBM is honored to collaborate with Pfizer, and put Watson for Drug Discovery to work to support efforts in bringing life-saving immunotherapies to doctors and patients worldwide.”

Takeda and Lightstone Ventures launch Cerevance


Takeda and Lightstone Ventures launched Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology, created in the Howard Hughes Medical Institute laboratory of Nathaniel Heintz, Ph.D. at the Rockefeller University.

Takeda will jumpstart the new company by providing a 25-person neuroscience research team from its Cambridge, United Kingdom site, including industry veteran Mark Carlton, Ph.D., fully equipped laboratory space, and licenses to a portfolio of preclinical and clinical stage drug programs. Cerevance is funded with $36 million that includes a $21.5 million Series A financing investment from Takeda and Lightstone Ventures, with each joining Cerevance’s Board of Directors.

“Seven of the ten leading causes of disability in the world are central nervous system disorders,” said Brad Margus, Cerevance Chief Executive Officer. “With a well capitalized, proven team and promising drug programs already underway, we hope to rapidly advance a pipeline of therapeutics into the clinic in parallel with scaling up a truly novel approach to brain diseases based on our new technology.”

“We are thrilled to assemble some of our best scientists, programs and discovery resources in a highly focused endeavor as part of our increased emphasis on leveraging external innovation,” said Andrew Plump, M.D., Ph.D., Chief Medical and Scientific Officer of Takeda. “When we announced the closure of our research site in Cambridge, UK, our goal was to find an innovative externalization home for our most promising CNS programs and scientists in an entrepreneurial setting. Cerevance is a great example of our new R&D strategy.”

“Lightstone is excited to lead the Series A in Cerevance and believes the combination of Nat Heintz’s expertise and platform technology, the proven and impassioned management team, and Takeda’s strong support represent a compelling early-stage investment opportunity,” said Jason Lettmann, Partner at Lightstone Ventures. “Cerevance is in a unique position to bring a breakthrough technology to the development of treatments for central nervous system diseases that affect millions of people worldwide.”

This is not the first time that Takeda, Heintz and Margus have joined forces. In 2009, Takeda invested in and later collaborated with CNS drug discovery start-up Envoy Therapeutics which included Heintz and Margus as founders and which also licensed a technology from the Rockefeller University. Takeda ultimately acquired Envoy in 2012.

Cerevance will have sites in both Massachusetts and the United Kingdom, surrounded by vibrant academic research ecosystems that support biotechnology and pharmaceutical companies.

Unither Pharmaceuticals: ORODIS® Innovative Orodispersible Dosage Forms


It is surprising that today, more than half of the population has difficulty taking their oral solid medications. One significant example concerns geriatric patients, for which swallowing problems can affect more than 70% of the elderly population thus can dramatically affect the risk of inobservance of treatments or may cause bad and risky practices such as the crushing of solid dosage forms. Another example concerns children who regularly refuse to take their medication due to bad taste. Indeed, there is an increasing demand from these patients to have access to more convenient medications. Furthermore, this trend is not limited to kids and elderly but may also concern, for example, on-the-go life style people who need to have an easy to take, easy to carry medication allowing to improve their chronic diseases treatment.

At UNITHER, we focus on improving life of patients while facilitating medications intake.

As a global leader in single unit dosage forms, we have developed technologies that enable line extensions and product differentiation exploiting lifestyle-related shifts in consumer needs. We constantly strive to provide our customers innovative solutions, competitive and sustainable, while always taking patient needs as a first consideration.

Our Research & Development teams worked during several years to build up a new and innovative technology platform dedicated to convenient solid oral dosage forms



OPTIMASK® Taste Masking Technology

Can be combined with ORODIS® Tablets and/or Granules


MATRIS® Modified Release Technology

Can be combined with ORODIS® Tablets and/or Granules




Visit Unither Pharmaceutical’s booth